ESMO Continues With Its Efforts to Secure the Timely Delivery of Innovative Medicines for Patients With Cancer and Prevent Medicines Shortages
Ahead of the plenary vote in the European Parliament (EP), held on 10 April 2024, ESMO wrote to the Political Groups Coordinators on the EP’s Committee on the Environment, Public Health and Food Safety (ENVI) to welcome its reports as a positive step towards reforming the European Union’s general pharmaceutical legislation, as it provides a once in a generation opportunity to improve the availability, accessibility and affordability of medicines for both cancer and rare cancer patients in the EU